IADR Abstract Archives
Methodology Development for Lidocaine Quantification by LCMS/MS
Objectives: Develop and validate an effective, selective, and rapid method for lidocaine and its main metabolite (monoethylglycinexylidide - MEGX) identification and quantification through liquid chromatography with tandem mass spectrometry (LC-MS/MS) in oral fluid samples.
Methods: All the analyses were carried out using the LC MS/MS 8040 Triple Quadrupole equipment. To identify and quantify lidocaine and the metabolite MEGX, a Shim-Pack XR-ODS 75 L × 2.0 column and a C18 precolumn were used at 40 °C, with a mixture of methanol and 25 mM ammonium acetate (70:30, v/v) with an injection flow rate of 0.3 ml/min. The peak areas for all components were integrated automatically using the LabSolutions software, version 5.97 (Shimadzu, Kyoto, Japan). The analytical method was developed and validated in accordance with the Analytical Validation Guidelines of National Health Surveillance Agency (ANVISA No. 166/2017) and the essential parameters evaluated were linearity, accuracy and precision, medium quality control (MQC), high quality control (HQC), limits of detection (LLOQ) and limits of quantification (LQC), stability and dilution.
Results: Positive MRM (multiple reaction monitoring) mode was used for identification and quantification by monitoring the transitions: Lidocaine: 235; 86.20 and 58.15 m/z. MEGX: 206.85; 58.15 and 30.15 m/z, precursor and products, respectively. The parameters evaluated for lidocaine and MEGX in saliva showed linearity between 2.4 and 1250 ng/mL, accuracy, precision, MQC-312.5 ng/mL, HQC-625 ng/mL, LLOQ-2.4 ng/mL, LQC-4.8ng/mL, stability, and dilution. All the parameters evaluated in methodology validation in saliva samples were stable and within the possible variations (< 15%) in each of the parameters evaluated.
Conclusions: The data presented demonstrated the possibility of a pharmacokinetic study, identifying and quantifying lidocaine and its main metabolite in saliva samples using LC-M/MS. The proposed analysis methodology proved to be efficient, fast, and promising for pharmacokinetic tests following the use of local anesthetics.
Methods: All the analyses were carried out using the LC MS/MS 8040 Triple Quadrupole equipment. To identify and quantify lidocaine and the metabolite MEGX, a Shim-Pack XR-ODS 75 L × 2.0 column and a C18 precolumn were used at 40 °C, with a mixture of methanol and 25 mM ammonium acetate (70:30, v/v) with an injection flow rate of 0.3 ml/min. The peak areas for all components were integrated automatically using the LabSolutions software, version 5.97 (Shimadzu, Kyoto, Japan). The analytical method was developed and validated in accordance with the Analytical Validation Guidelines of National Health Surveillance Agency (ANVISA No. 166/2017) and the essential parameters evaluated were linearity, accuracy and precision, medium quality control (MQC), high quality control (HQC), limits of detection (LLOQ) and limits of quantification (LQC), stability and dilution.
Results: Positive MRM (multiple reaction monitoring) mode was used for identification and quantification by monitoring the transitions: Lidocaine: 235; 86.20 and 58.15 m/z. MEGX: 206.85; 58.15 and 30.15 m/z, precursor and products, respectively. The parameters evaluated for lidocaine and MEGX in saliva showed linearity between 2.4 and 1250 ng/mL, accuracy, precision, MQC-312.5 ng/mL, HQC-625 ng/mL, LLOQ-2.4 ng/mL, LQC-4.8ng/mL, stability, and dilution. All the parameters evaluated in methodology validation in saliva samples were stable and within the possible variations (< 15%) in each of the parameters evaluated.
Conclusions: The data presented demonstrated the possibility of a pharmacokinetic study, identifying and quantifying lidocaine and its main metabolite in saliva samples using LC-M/MS. The proposed analysis methodology proved to be efficient, fast, and promising for pharmacokinetic tests following the use of local anesthetics.